Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Villalvazo, P; Marzal-Alfaro, B; Garcia-Alfonso, P; Revuelta-Herrero, JL; Thomas, F; Lopez-Tarruella, S; Garcia-Gonzalez, X; Calvo, A; Yakoubi, M; Salvador-Martin, S; Lopez-Lopez, F; Aguilar, I; Sanjurjo-Saez, M; Martin, M; Lopez-Fernandez, LA.

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach

Journal of Personalized Medicine. 2021; 11(8): Nº de citas: 7 [doi:10.3390/jpm11080792]

Gutierrez-Seijo, A; Garcia-Martinez, E; Barrio-Alonso, C; Pareja-Malagon, M; Acosta-Ocampo, A; Fernandez-Santos, ME; Puig-Kroger, A; Parra-Blanco, V; Mercader, E; Marquez-Rodas, I; Aviles-Izquierdo, JA; Samaniego, R; Sanchez-Mateos, P.

CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma

Cancers. 2021; 13(16): Nº de citas: 19 [doi:10.3390/cancers13163943]

Mandala, M; Larkin, J; Ascierto, PA; Del Vecchio, M; Gogas, H; Cowey, CL; Arance, A; Dalle, S; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez, I; Butler, MO; Di Giacomo, AM; Lutzky, J; De la Cruz-Merino, L; Atkinson, V; Arenberger, P; Hill, A; Fecher, L; Millward, M; Khushalani, NI; de Pril, V; Lobo, M; Weber, J.

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Journal for ImmunoTherapy of Cancer. 2021; 9(8): Nº de citas: 17 [doi:10.1136/jitc-2021-003188]

Sereno, M; Jimenez-Gordo, AM; Baena-Espinar, J; Aguado, C; Mielgo, X; Pertejo, A; Alvarez-Alvarez, R; Sanchez, A; Lopez, JL; Molina, R; Lopez-Alfonso, A; Hernandez, B; Chiara, LE; Martin, AM; Lopez-Martin, A; Dorta, M; Collazo-Lorduy, A; Casado, E; de Molina, AR; Colmenarejo, G.

A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis

Cancers. 2021; 13(16): Nº de citas: 14 [doi:10.3390/cancers13164205]

Escudero-Vilaplana, V; Collado-Borrell, R; del Monte-Millan, M; Hoyo-Munoz, A; Martinez-Sagrera, PG; Revuelta-Herrero, JL; Marzal-Alfaro, B; Gonzalez-Haba, E; Cobo, SLT; Gilarranz, YJ; Herranz, A; Sanjurjo, M; Martin, M.

Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

SUPPORTIVE CARE IN CANCER. 2021; 29(8): 4673-4681 Nº de citas: 1 [doi:10.1007/s00520-021-06016-z]

Jantus-Lewintre, E; Sureda, BM; Larriba, JLG; Rodriguez-Abreu, D; Juan, O; Blasco, A; Domine, M; Pulla, MP; Garde, J; Alvarez, R; Maestu, I; de Carrion, RP; Artal, A; Rolfo, C; de Castro, J; Guillot, M; Oramas, J; de las Penas, R; Ferrera, L; Martinez, N; Serra, O; Rosell, R; Camps, C; Grp Espanol Canc Pulmon GECP.

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

Frontiers in Oncology. 2021; 11: 695038-695038 Nº de citas: 7 [doi:10.3389/fonc.2021.695038]

Provencio, M; Gallego, JMM; Calles, A; Antonanzas, M; Pangua, C; Rubio, XM; Nadal, E; Castro, RL; Lopez-Martin, A; Del Barco, E; Domine, M; Franco, F; Diz, P; Sandoval, C; Girona, ES; Sullivan, I; Sala, MA; Ledo, GG; Cucurull, M; Mosquera, J; Martinez, M; Chara, LE; Arriola, E; Herrera, BE; Jarabo, JR; Alvarez, RA; Baena, J; Cao, MG.

Lung cancer patients with COVID-19 in Spain: GRAVID study

LUNG CANCER. 2021; 157: 109-115 Nº de citas: 30 [doi:10.1016/j.lungcan.2021.05.014]

Curigliano, G; Martin, M; Jhaveri, K; Beck, JT; Tortora, G; Fazio, N; Maur, M; Hubner, RA; Lahner, H; Donnet, V; Ajipa, O; Li, Z; Blumenstein, L; Andre, F.

Clinical Trial

EUROPEAN JOURNAL OF CANCER. 2021; 151: 49-62 Nº de citas: 22 [doi:10.1016/j.ejca.2021.03.042]

Aviles-Izquierdo, JA; Mercader-Cidoncha, E; Escat-Cortes, JL; Marquez-Rodas, I; Parra-Blanco, V; Rodriguez-Lomba, E.

When is it worth performing lymphadenectomy in patients with melanoma micrometastases? A 20-year experience retrospective analysis

Cirugia y Cirujanos. 2021; 89(4): 457-460 [doi:10.24875/CIRU.20000545]

Johnston, S; O'Shaughnessy, J; Martin, M; Huober, J; Toi, M; Sohn, J; Andre, VAM; Martin, HR; Hardebeck, MC; Goetz, MP.

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Npj Breast Cancer. 2021; 7(1): 80-80 Nº de citas: 49 [doi:10.1038/s41523-021-00289-7]

Romera, A; Cebollero, M; Romero-Gomez, B; Carricondo, F; Zapatero, S; Garcia-Aldao, U; Martin-Albo, L; Ortega, J; Vara, E; Garutti, I; Simon, C.

Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery

Biomed Research International. 2021; 2021: 6630232-6630232 Nº de citas: 9 [doi:10.1155/2021/6630232]

Esteban, E; Exposito, F; Crespo, G; Lambea, J; Pinto, A; Puente, J; Arranz, JA; Redrado, M; Rodriguez-Antona, C; de Andrea, C; Lopez-Brea, M; Redin, E; Rodriguez, A; Serrano, D; Garcia, J; Grande, E; Castellano, D; Calvo, A.

Circulating Levels of the Interferon-gamma-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy

Cancers. 2021; 13(11): Nº de citas: 15 [doi:10.3390/cancers13112849]

Gyawali, B; de Vries, EGE; Dafni, U; Amaral, T; Barriuso, J; Bogaerts, J; Calles, A; Curigliano, G; Gomez-Roca, C; Kiesewetter, B; Oosting, S; Passaro, A; Pentheroudakis, G; Piccart, M; Roitberg, F; Tabernero, J; Tarazona, N; Trapani, D; Wester, R; Zarkavelis, G; Zielinski, C; Zygoura, P; Cherny, NI.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

ESMO Open. 2021; 6(3): 100117-100117 Nº de citas: 56 [doi:10.1016/j.esmoop.2021.100117]

Hamilton, E; Cortes, J; Ozyilkan, O; Chen, SC; Petrakova, K; Manikhas, A; Jerusalem, G; Hegg, R; Huober, J; Chapman, SC; Lu, Y; Hardebeck, MC; Bear, MM; Johnston, EL; Martin, M.

nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

Clinical Breast Cancer. 2021; 21(3): 181 Nº de citas: 36 [doi:10.1016/j.clbc.2020.09.011]

Illini, O; Hochmair, MJ; Fabikan, H; Weinlinger, C; Tufman, A; Swalduz, A; Lamberg, K; Hashemi, SMS; Huemer, F; Vikstrom, A; Wermke, M; Absenger, G; Addeo, A; Banerji, S; Calles, A; Clarke, S; Di Maio, M; Durand, A; Duruisseaux, M; Itchins, M; Kaaranien, OS; Krenn, F; Laack, E; de Langen, AJ; Mohorcic, K; Pall, G; Passaro, A; Prager, G; Rittmeyer, A; Rothenstein, J; Schumacher, M; Woll, E; Valipour, A.

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Therapeutic Advances in Medical Oncology. 2021; 13: Nº de citas: 44 [doi:10.1177/17588359211019675]

Aapro, M; Scotte, F; Escobar, Y; Celio, L; Berman, R; Franceschetti, A; Bell, D; Jordan, K.

Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data

ONCOLOGIST. 2021; 26(6): 1073-1082 Nº de citas: 39 [doi:10.1002/onco.13716]

Kuemmel, S; Tondini, CA; Abraham, J; Nowecki, Z; Itrych, B; Hitre, E; Karaszewska, B; Juarez-Ramiro, A; Morales-Vasquez, F; Perez-Garcia, JM; Cardona-Huerta, S; Monturus, E; Sequi, M; Restuccia, E; Benyunes, M; Martin, M.

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

BREAST CANCER RESEARCH AND TREATMENT. 2021; 187(2): 467-476 Nº de citas: 18 [doi:10.1007/s10549-021-06145-3]

Garcia-Pardo, M; Ortega, L; Fernandez-Acenero, MJ; Alfonso, PG; Martin, M; Munoz, AJ.

Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study

Journal of Gastrointestinal Cancer. 2021; 52(2): 814-818 Nº de citas: 4 [doi:10.1007/s12029-021-00622-0]